Skip to content
lifestyle.clientim.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AB Science
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
September 29, 2026
AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
June 2, 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
May 25, 2026
AB Science reports its revenues for the year 2025 and provides an update on its activities
May 13, 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
April 27, 2026
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
April 20, 2026
AB Science provides an update on its clinical development program.
April 16, 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
February 24, 2026